A key FDA decision could pave the way for higher sales of the company's flagship drug.
News & Analysis: Flexion Therapeutics
FLXN earnings call for the period ending September 30, 2019.
For a few companies, the second half of 2019 will probably work out better than investors dared hope for earlier this year.
FLXN earnings call for the period ending June 30, 2019.
Axsome Therapeutics, Flexion Therapeutics, and UroGen Pharma gave investors reasons for excitement.
FLXN earnings call for the period ending March 31, 2019.
The pharma company announced first-quarter 2019 operating results.
FLXN earnings call for the period ending December 31, 2018.
The company reported preliminary full-year 2018 results and set expectations for a solid year of growth in 2019.
The small-cap biopharma announced third-quarter 2018 operating results and a business update.